NIKKEI 225
27,781.02+497.43(+1.82%)HANG SENG
26,235.80+274.77(+1.06%)CRUDE OIL
71.18-2.77(-3.75%)GOLD FUTURES
1,818.00+0.80(+0.04%)DOW
34,956.43+20.96(+0.06%)BTC-GBP
28,608.31-1,176.87(-3.95%)
Saniona AB (publ) (SANION.ST)
| Previous close | 19.28 |
| Open | 19.30 |
| Bid | 18.14 x 0 |
| Ask | 18.20 x 0 |
| Day's range | 18.04 - 19.64 |
| 52-week range | 15.40 - 44.50 |
| Volume | 307,252 |
| Avg. volume | 178,369 |
| Market cap | 1.13B |
| Beta (5Y monthly) | 0.66 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.06 |
| Earnings date | 26 Aug 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 77.50 |
- Globe Newswire
Saniona Receives U.S. FDA Orphan Drug Designation for Tesomet in Hypothalamic Obesity
PRESS RELEASE July 26, 2021 Tesomet is the first and only investigational treatment for hypothalamic obesity to receive orphan drug designation Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Tesomet for the treatment of hypothalamic obesity (HO). Tesomet is the first and only investigational treatment for HO to receive orphan drug designation. Sanio
- Globe Newswire
Saniona secures SEK 87 million ($10 million) non-dilutive term loan
PRESS RELEASE July 14, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it has entered into a non-dilutive term loan agreement for SEK 87 million ($10 million) with Formue Nord Fokus A/S. Proceeds from the loan will be used to support Saniona’s clinical development programs and for general working capital purposes. Rami Levin, President & Chief Executive Officer of Saniona, commented, “We just initiated a Phase 1 trial of SAN71
- Globe Newswire
Saniona Initiates Phase 1 Clinical Trial of SAN711
PRESS RELEASE June 30, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it has dosed the first patient in a Phase 1 clinical trial of SAN711, a novel molecule derived from Saniona’s proprietary ion channel drug discovery engine. SAN711 is a first-in-class positive allosteric modulator of GABA-A α3 receptors and may be applicable in the treatment of rare neuropathic disorders. Data from the trial are expected in the first half o
